Editorial: Therapeutics Initiative has proven its worth
NDP says it will restore funding if elected; Liberals should make same promise
VANCOUVER SUN EDITORIAL MAY 3, 2013
A little less than 15 years ago a new class of anti-arthritis drugs was introduced to the Canadian market. Yet within a few years, a number of such drugs, including rofecoxib (Vioxx) and valdecoxib (Bextra), were withdrawn from the market thanks to the harms they caused to some users.